- Home
- MQT vs PRQR Comparison
MQT vs PRQR Comparison
Compare MQT & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQT
- PRQR
- Stock Information
- Founded
- MQT 1992
- PRQR 2012
- Country
- MQT United States
- PRQR Netherlands
- Employees
- MQT N/A
- PRQR N/A
- Industry
- MQT Investment Bankers/Brokers/Service
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- MQT Finance
- PRQR Health Care
- Exchange
- MQT Nasdaq
- PRQR Nasdaq
- Market Cap
- MQT 218.4M
- PRQR 232.8M
- IPO Year
- MQT N/A
- PRQR 2014
- Fundamental
- Price
- MQT $10.02
- PRQR $2.25
- Analyst Decision
- MQT
- PRQR Strong Buy
- Analyst Count
- MQT 0
- PRQR 8
- Target Price
- MQT N/A
- PRQR $8.88
- AVG Volume (30 Days)
- MQT 52.5K
- PRQR 337.6K
- Earning Date
- MQT 01-01-0001
- PRQR 11-06-2025
- Dividend Yield
- MQT 4.60%
- PRQR N/A
- EPS Growth
- MQT N/A
- PRQR N/A
- EPS
- MQT N/A
- PRQR N/A
- Revenue
- MQT N/A
- PRQR $20,129,184.00
- Revenue This Year
- MQT N/A
- PRQR N/A
- Revenue Next Year
- MQT N/A
- PRQR N/A
- P/E Ratio
- MQT N/A
- PRQR N/A
- Revenue Growth
- MQT N/A
- PRQR 8.65
- 52 Week Low
- MQT $8.59
- PRQR $1.07
- 52 Week High
- MQT $10.67
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- MQT 77.98
- PRQR 51.37
- Support Level
- MQT $9.47
- PRQR $2.21
- Resistance Level
- MQT $9.56
- PRQR $2.50
- Average True Range (ATR)
- MQT 0.08
- PRQR 0.14
- MACD
- MQT 0.05
- PRQR 0.01
- Stochastic Oscillator
- MQT 98.52
- PRQR 37.50
About MQT Blackrock MuniYield Quality Fund II Inc.
BLACKROCK MUNIYIELD QUALITY FUND II, INC. is a closed-end fund. Its objective is to provide shareholders with as high a level of current income exempt from federal income taxes as is consistent with its investment policies and prudent investment management. It invests in various sectors such as Transportation, Utilities, Health, County/City/Special District/School District, Education, Housing, Corporate, and Tobacco.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.